1
|
de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol 2024; 151:106747. [PMID: 38460288 DOI: 10.1016/j.oraloncology.2024.106747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Accepted: 03/05/2024] [Indexed: 03/11/2024]
Affiliation(s)
- L Guimaraes de Sousa
- Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - S Liu
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - P Bhosale
- Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M Altan
- Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - W Darbonne
- Roche/Genentech, South San Francisco, CA, USA
| | - K Schulze
- Roche/Genentech, South San Francisco, CA, USA
| | - S Dervin
- Roche/Genentech, South San Francisco, CA, USA
| | - C Yun
- Roche/Genentech, South San Francisco, CA, USA
| | - A Mahvash
- Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - A Verma
- Department of Pathology, Yale-New Haven Hospital, New Haven, CT, USA
| | - A Futreal
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - S Gite
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - E Parra Cuentas
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - W C Cho
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - I Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - J C Yao
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - S E Woodman
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - D M Halperin
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - R Ferrarotto
- Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
2
|
Buchner JA, Kofler F, Mayinger MC, Brunner TB, Wittig A, Menze B, Zimmer C, Meyer B, Guckenberger M, Andratschke N, Shafie RE, Rogers S, Schulze K, Blanck O, Zamboglou C, Grosu A, Combs SE, Bernhardt D, Wiestler B, Peeken JC. What MRI Sequences are Necessary for Automated Neural Network-Based Metastasis Segmentation - An Ablation Study. Int J Radiat Oncol Biol Phys 2023; 117:e704-e705. [PMID: 37786065 DOI: 10.1016/j.ijrobp.2023.06.2195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Brain metastasis (BM) delineation is a time-consuming process in both daily clinical practice and research. Automated BM segmentation algorithms can be used to assist in this task. Most approaches to brain tumor segmentation, such as algorithms trained on the BraTS challenge, use four magnetic resonance imaging (MRI) sequences as input, making them susceptible to missing or corrupted sequences and increase the number of sequences necessary for MRI RT planning. The goal of this project is to compare neural networks with different combinations of input sequences for the segmentation of the contrast-enhancing metastasis and the surrounding FLAIR hyperintense edema. All models were tested in a multicenter international external test cohort. This allows us to determine which MRI sequences are needed for effective automated segmentations. MATERIALS/METHODS In total, we had T1-weighted sequences without (T1) and with contrast enhancement (T1-CE), T2-weighted sequences (T2), and T2 fluid-attenuated inversion recovery (FLAIR) sequences from 339 patients with at least one brain metastasis from seven centers available. Preprocessing yielded co-registered, skull-stripped sequences with an isotropic resolution of 1 millimeter. The contrast-enhancing metastasis as well as the surrounding FLAIR hyperintense edema were manually segmented to create reference labels. A baseline 3D U-Net with all four sequences as well as six additional U-Nets with different clinically plausible combinations (T1-CE; T1; FLAIR; T1-CE+FLAIR; T1-CE+T1+FLAIR; T1-CE+T1) of input sequences were trained on a cohort of 239 patients from two centers and subsequently tested on an external cohort of 100 patients from the remaining five centers. RESULTS All models that included T1-CE in their selected sequences showed similar performance for metastasis segmentation with a median Dice similarity coefficient (DSC) of 0.93-0.96. T1-CE alone likewise achieved a performance of 0.96 (IQR 0.93-0.97). The model trained with only FLAIR performed worse (DSC = 0.73, IQR 0.54-0.84). For edema segmentation, models that included both T1-CE and FLAIR performed best (median DSC = 0.93), while the remaining four models without simultaneous inclusion of these two sequences (T1-CE; T1; FLAIR; T1-CE+T1) reached a median DSC of 0.81-0.89. CONCLUSION Automatic segmentation of brain metastases with less than four input sequences is feasible with minimal or no loss of quality. A T1-CE-only protocol suffices for metastasis segmentation. In contrast, for edema segmentation, the combination of T1-CE and FLAIR seems to be important. Missing either T1-CE or FLAIR decreases performance. These findings may improve future imaging routines by omitting unnecessary sequences, thus speeding up procedures in daily clinical practice while allowing for optimal neural network-based target definitions.
Collapse
Affiliation(s)
- J A Buchner
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - F Kofler
- Helmholtz AI, Helmholtz Zentrum Munich, Munich, Germany; Department of Informatics, Technical University of Munich, Munich, Germany
| | - M C Mayinger
- Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - T B Brunner
- Medical University of Graz, Dept. of Radiation Oncology, Graz, Austria; Department of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany
| | - A Wittig
- Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Friedrich-Schiller University, Jena, Germany
| | - B Menze
- Department of Informatics, Technical University of Munich, Munich, Germany
| | - C Zimmer
- Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - B Meyer
- Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - N Andratschke
- Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - R El Shafie
- Heidelberg Institute for Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg, Germany; Department of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
| | - S Rogers
- Radiation Oncology Center KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland
| | - K Schulze
- Department of Radiation Oncology, General Hospital Fulda, Fulda, Germany
| | - O Blanck
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - C Zamboglou
- Department of Radiation Oncology, German Oncology Center, European University of Cyprus, Limassol, Cyprus; Department of Radiation Oncology, University of Freiburg - Medical Center, Freiburg, Germany
| | - A Grosu
- Department of Radiation Oncology, University of Freiburg - Medical Center, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany
| | - S E Combs
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Center Munich, Munich, Germany
| | - D Bernhardt
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
| | - B Wiestler
- Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany
| | - J C Peeken
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Center Munich, Munich, Germany
| |
Collapse
|
3
|
Bernhardt D, Peeken JC, Kehl V, Eitz K, Guckenberger M, Andratschke N, Mayinger MC, Lindel K, Dieckmann K, El Shafie R, Debus J, Riesterer O, Rogers S, Blanck O, Wolff R, Grosu A, Bilger A, Henkenberens C, Schulze K, Gani C, Müller AC, Radlanski K, Janssen S, Ferentinos K, Combs SE. Post-Operative Stereotactic Radiotherapy for Resected Brain Metastases: Results of the Multicenter Analysis (AURORA) of the German Working Group "Stereotactic Radiotherapy". Int J Radiat Oncol Biol Phys 2023; 117:e87-e88. [PMID: 37786203 DOI: 10.1016/j.ijrobp.2023.06.842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) While the results of prospective studies support the use of postoperative stereotactic radiotherapy (RT) to the resection cavity (RC) as the standard of care after surgery, there are several issues that need to be investigated such as factors for improving local control, risk of leptomeningeal disease and radiation necrosis. Further, the optimal dose and fractionation is still under debate. MATERIALS/METHODS The working group "Stereotactic Radiotherapy" of the German Society of Radiation Oncology (DEGRO) analyzed its multi-institutional database with 661 patients who received postoperative stereotactic RT to the RC. Treatment was performed at 13 centers between 2008 and 2021. Patient characteristics, treatment details, and follow-up data including overall survival (OS), local control (LC) were evaluated. Cox Regression and Kaplan-Meier curves with Log-rank Tests were calculated for selected variables. RESULTS In this retrospective study, overall survival was 61.5% at 1 year, 47.6% at 2 years, and 35.5% at 3 years, and local control was 84.6% at 1 year, 74.8% at 2 years, and 72.8% at 3 years. 96% of patients were treated with hypofractionated stereotactic radiotherapy (HSRT), only 26 patients received single fraction radiosurgery (4%). Prognostic factors associated with overall survival were Karnofsky Performance Status, RPA and GPA class, controlled primary tumor and absence of extracranial metastases, whereas prognostic factor associated with local control was planning target volume (23 mL or less). CONCLUSION HSRT is the most common fractionation form in the treatment of RCs in this multicenter analysis. This approach results in excellent OS and LC outcomes. OS in patients with resected brain metastases is mainly influenced by performance status. In regard to local control, RT of large cavities remain a challenge with significantly worse outcome.
Collapse
Affiliation(s)
- D Bernhardt
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Germany, Munich, Germany
| | - J C Peeken
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Center Munich, Munich, Germany
| | - V Kehl
- Institute for AI and Informatics in Medicine, Munich, NA, Germany
| | - K Eitz
- Department of Radiation Oncology - Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH), Zurich, Switzerland
| | - N Andratschke
- Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - M C Mayinger
- Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
| | - K Lindel
- Municipal Hospital, Department for Radiation Oncology, Karlsruhe, Germany
| | - K Dieckmann
- Department of Radiation Oncology, Vienna, Austria
| | - R El Shafie
- 8Department of Radiation Oncology, University Hospital Göttingen, Göttingen, Germany
| | - J Debus
- CCU Translational Radiation Oncology, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Radiation Oncology University Hospital Heidelberg, Heidelberg, Germany
| | - O Riesterer
- Center for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland
| | - S Rogers
- Radiation Oncology Center KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland
| | - O Blanck
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - R Wolff
- University Hospital Frankfurt, Department of Neurosurgery, Frankfurt, Germany
| | - A Grosu
- German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany; Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - A Bilger
- Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - C Henkenberens
- Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany
| | - K Schulze
- Klinikum Fulda, 36251 Bad Hersfeld, Germany
| | - C Gani
- Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
| | - A C Müller
- Department of Radiotherapy, Klinikum Ludwigsburg, Ludwigsburg, Germany
| | - K Radlanski
- Radiation Oncology and Radiotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - S Janssen
- Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
| | - K Ferentinos
- Radiation Oncology Department, German Oncology Center, Limassol, Cyprus
| | - S E Combs
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Institute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany
| |
Collapse
|
4
|
Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00339-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
5
|
Lee J, Sepesi B, Toloza E, Lin J, Pass H, Johnson B, Heymach J, Johnson M, Ding B, Schulze K, Zhu Q, Ngiam C, Brandão E, Bara I, Chaft J. EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Vogel A, Boeck S, Waidmann O, Bitzer M, Wenzel P, Belle S, Springfeld C, Schulze K, Weinmann A, Lindig U, Trautwein C, Dechow T, Lammert F, Plentz R, Koehne CH, Kunzmann V, Maenz M, Kirstein M, Saborowski A. 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Oezkan F, Hilz S, Grindheim J, Wallace A, Seweryn M, Reuben A, Zhang J, Owen D, Nicholas A, Yadav M, Nagarkar D, de Almeida P, Ebert P, Osborne E, Johnson A, Lee J, Bunn P, Johnson B, Chaft J, Kris M, Rusch V, Schulze K, Kwiatkowski D, Wistuba I, Carbone D. OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
8
|
Friedman C, Swanton C, Spigel D, Bose R, Burris H, Yu W, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney C, Hainsworth J, Meric-Bernstam F, Kurzrock R. 66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
9
|
Kris M, Grindheim J, Chaft J, Lee J, Johnson B, Rusch V, Bunn P, Pass H, Schum E, Carlisle J, Weyant M, Nicholas A, Johnson A, Shames D, Wistuba I, Carbone D, Schulze K, Kwiatkowski D. 1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
10
|
Kutsaev SV, Agustsson R, Berry R, Boucher S, Bruhwiler D, Schulze K, Smirnov AY, Taletski K. Ir-192 radioisotope replacement with a hand-portable 1 MeV Ku-band electron linear accelerator. Appl Radiat Isot 2021; 179:110029. [PMID: 34814009 DOI: 10.1016/j.apradiso.2021.110029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 08/24/2021] [Accepted: 11/10/2021] [Indexed: 11/26/2022]
Abstract
Although linear accelerators are used in many security, industrial and medical applications, the existing technologies are too large and expensive for several critical applications such as radioactive source replacement, field radiography and mobile cargo scanners. One of the main requirements for these sources is to be highly portable to allow field operation. In response to this problem, RadiaBeam has designed a hand-portable 1 MeV X-ray source, scalable to higher energies, based on Ku-band split electron linac, that can be used for Ir-192 radioisotope replacement. In this paper, we present its multiphysics and engineering design studies, as well as an accelerating structure prototype along with RF measurements.
Collapse
Affiliation(s)
- S V Kutsaev
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA.
| | - R Agustsson
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA
| | - R Berry
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA
| | - S Boucher
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA
| | | | - K Schulze
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA
| | - A Yu Smirnov
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA
| | - K Taletski
- RadiaBeam Technologies, LLC, Santa Monica, CA, 90404, USA
| |
Collapse
|
11
|
Hariton W, Schulze K, Overmiller A, Mahoney M, Borradori L, Sayar BS, Galichet A, Müller E. 320 Desmoglein 3-mediated mechanical transadhesion controls epithelial stem cell quiescence. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Vanderwalde A, Lu M, Maund S, Huntley M, Incerti D, Fine A, Tolba K, Jin D, Bourla A, Sondhi A, Tromanhauser M, Daniel D, Tilford J, Mcfarlane J, Lakhanpal S, Oxnard G, Schulze K. P10.14 ctDNA and Real-World Response (rwR) in Patients With Lung Cancer From A Prospective Real-World Clinico-Genomic (PCG) Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.319] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Oezkan F, Seweryn M, Pietrzak M, Byun W, Owen D, Schulze K, Nicholas A, Hilz S, Grindheim J, Johnson A, Kwiatkowski D, Wistuba I, Johnson B, Kris M, Rusch V, Lee J, Lozanski G, Carbone D. MA09.01 LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.152] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
|
15
|
Lee J, Wistuba I, Ngiam C, Yu W, Schulze K, Rocha M, Bara I, Carbone D, Johnson B, Kwiatkowski D, Center M, Chaft J. P03.04 Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Walia G, Lu M, Bourla A, Santos E, Schulze K, Cabili M, Williams E, Mirkovic N, Dicecca R, Lee S, Fang B, Schwartzberg L, Herbst R, Chiang A. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Lee J, Chaft J, Nicholas A, Patterson A, Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, Owen D, Finley D, Mcnamee C, Blasberg J, Garon E, Mitchell J, Doebele R, Baciewicz F, Nagasaka M, Pass H, Schulze K, Phan S, Johnson A, Bunn P, Johnson B, Kris M, Kwiatkowski D, Wistuba I, Carbone D, Rusch V. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.320] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
18
|
Carbone D, Lee J, Kris M, Wistuba I, Kwiatkowski D, Owen D, Bunn P, Johnson B, Oezkan F, Tang Y, Parra E, Lozanski G, Rivard C, Schulze K, Nicholas A, Johnson A, Grindheim J, Shames D, Phan S, Toloza E, Haura E, Mcnamee C, Gainor J, Patterson A, Waqar S, Raz D, Reckamp K, Finley D, Rusch V, Chaft J, Abel J. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.294] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Anderson M, Schulze K, Cassini A, Plauchoras D, Mossialos E. Strengthening implementation of antimicrobial resistance national action plans. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.1200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Antimicrobial resistance is one of the major challenges of our time. Countries use national action plans as a mechanism to build engagement among stakeholders and coordinate a range of actions across human, animal, and environmental health. However, implementation of recommended policies such as stewardship of antimicrobials, infection prevention and control, and stimulating research and development of novel antimicrobials and alternatives remains inconsistent. Improving the quality of governance within antimicrobial resistance national action plans is an essential step to improving implementation. To date, no systematic approach to governance of national action plans on AMR exists. To address this issue, we aimed to develop the first governance framework to offer guidance for both the development and assessment of national action plans on AMR. We reviewed health system governance framework reviews to inform the basic structure of our framework, international guidance documents from WHO, the Food and Agriculture Organization, the World Organisation for Animal Health, and the European Commission, and sought the input of 25 experts from international organisations, government ministries, policy institutes, and academic institutions to develop and refine our framework. The framework consists of 18 domains with 52 indicators that are contained within three governance areas: policy design, implementation tools, and monitoring and evaluation. Countries must engage with a cyclical process of continuous design, implementation, monitoring and evaluation to achieve these aims.
Collapse
Affiliation(s)
- M Anderson
- Department of Health Policy, London School of Economics and Political Science, London, UK
| | - K Schulze
- Department of Health Policy, London School of Economics and Political Science, London, UK
| | - A Cassini
- European Centre for Disease Prevention and Control, Solna, Sweden
| | - D Plauchoras
- Infection Prevention and Control Global Unit, WHO, Geneva, Switzerland
| | - E Mossialos
- Department of Health Policy, London School of Economics and Political Science, London, UK
| |
Collapse
|
20
|
Theelen WSME, Krijgsman O, Monkhorst K, Kuilman T, Peters DDGC, Cornelissen S, Ligtenberg MA, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Schulze K. Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma. J Transl Med 2020; 18:271. [PMID: 32620126 PMCID: PMC7333331 DOI: 10.1186/s12967-020-02436-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 06/24/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in dissecting the different components of the immune infiltrate. As gene expression analysis also provides information regarding tumor cells, differences in interactions between the immune system and specific tumor characteristics can also be explored. This study aims to gain further insights in the composition of the tumor immune infiltrate and to correlate these components to histology and overall survival in non-small cell lung cancer (NSCLC). METHODS Archival tissues from 530 early stage, resected NSCLC patients with annotated tumor and patient characteristics were analyzed using the NanoString nCounter Analysis system. RESULTS Unsupervised clustering of the samples was mainly driven by the overall level of inflammation, which was not correlated with survival in this patient set. Adenocarcinoma (AD) showed a significantly higher degree of immune infiltration compared to squamous cell carcinoma (SCC). A 34-gene signature, which did not correlate with the overall level of immune infiltration, was identified and showed an OS benefit in SCC. Strikingly, this benefit was not observed in AD. This difference in OS in SCC specifically was confirmed in two independent NSCLC cohorts. The highest correlation between expression of the 34-gene signature and specific immune cell populations was observed for NK cells, but although a plausible mechanism for NK cell intervention in tumor growth could be established in SCC over AD, this could not be translated back to immunohistochemistry, which showed that NK cell infiltration is scarce irrespective of histology. CONCLUSIONS These findings suggest that the ability of immune cell infiltration and the interaction between tumor and immune cells may be different between AD and SCC histology and that a subgroup of SCC tumors seems more susceptible to Natural Killer cell recognition and killing, whereas this may not occur in AD tumors. A highly sensitive technique like NanoString was able to detect this subgroup based on a 34-gene signature, but further research will be needed to assist in explaining the biological rationale of such low-level expression signatures.
Collapse
Affiliation(s)
- W S M E Theelen
- Department of Thoracic Oncology, The Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, The Netherlands.
| | - O Krijgsman
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - K Monkhorst
- Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - T Kuilman
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- Neogene Therapeutics, Amsterdam, The Netherlands
| | - D D G C Peters
- Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S Cornelissen
- Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M A Ligtenberg
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S M Willems
- Department of Pathology, University Medical Centre Groningen, Groningen, The Netherlands
| | | | - C J M van Noesel
- Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
| | - D S Peeper
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M M van den Heuvel
- Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - K Schulze
- Oncology Biomarker Development, Genentech Inc, South San Francisco, USA
| |
Collapse
|
21
|
Walshe M, McDonald C, Taylor M, Zhao J, Sham P, Grech A, Schulze K, Bramon E, Murray RM. Obstetric complications in patients with schizophrenia and their unaffected siblings. Eur Psychiatry 2020; 20:28-34. [PMID: 15642440 DOI: 10.1016/j.eurpsy.2004.07.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2003] [Accepted: 07/21/2004] [Indexed: 10/26/2022] Open
Abstract
AbstractObjectiveWe sought to explore whether obstetric complications (OCs) are more likely to occur in the presence of familial/genetic susceptibility for schizophrenia or whether they themselves represent an independent environmental risk factor for schizophrenia.MethodsThe presence of OCs was assessed through maternal interview on 216 subjects, comprising 36 patients with schizophrenia from multiply affected families, 38 of their unaffected siblings, 31 schizophrenic patients with no family history of psychosis, 51 of their unaffected siblings and 60 normal comparison subjects. We examined the familiality of OCs and whether OCs were commoner in the patient and sibling groups than in the control group.ResultsOCs tended to cluster within families, especially in multiply affected families. Patients with schizophrenia, especially those from multiply affected families, had a significantly higher rate of OCs compared to normal comparison subjects, but there was no evidence for an elevated rate of OCs in unaffected siblings.ConclusionOur data provides little evidence for a link between OCs and genetic susceptibility to schizophrenia. If high rates of OCs are related to schizophrenia genes, this relationship is weak and will only be detected by very large sample sizes.
Collapse
Affiliation(s)
- M Walshe
- Division of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, London, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 2020; 31:412-421. [PMID: 32067683 PMCID: PMC9743163 DOI: 10.1016/j.annonc.2019.11.018] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 11/08/2019] [Accepted: 11/28/2019] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. PATIENTS AND METHODS MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR). RESULTS As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred. CONCLUSIONS Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
Collapse
Affiliation(s)
- R. Kurzrock
- Moores Cancer Center, UC San Diego, San Diego,Correspondence to: Dr Razelle Kurzrock, Moores Cancer Center, UC San Diego, 3855 Health Sciences Dr. #1503, La Jolla, CA 92093, USA. Tel: +1-858-246-1102; Fax: +1-858-246-1915, (R. Kurzrock)
| | - D. W. Bowles
- Department of Medicine, University of Colorado Denver, Aurora
| | - H. Kang
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore
| | - F. Meric-Bernstam
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston
| | - J. Hainsworth
- Oncology Department, Sarah Cannon Research Institute, Nashville,Tennessee Oncology, PLLC, Nashville
| | - D. R. Spigel
- Oncology Department, Sarah Cannon Research Institute, Nashville,Tennessee Oncology, PLLC, Nashville
| | - R. Bose
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis
| | - H. Burris
- Oncology Department, Sarah Cannon Research Institute, Nashville,Tennessee Oncology, PLLC, Nashville
| | - C. J. Sweeney
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - M. S. Beattie
- Department of Product Development, Medical Affairs, F. Hoffmann-La Roche, South San Francisco, USA
| | - S. Blotner
- Department of Biostatistics, South San Francisco, USA
| | - K. Schulze
- Department of Oncology Biomarker Development, South San Francisco, USA
| | - V. Cuchelkar
- Department of BioOncology, Genentech, Inc., South San Francisco, USA
| | - C. Swanton
- Department of Tumour Biology, Francis Crick Institute, London, UK
| |
Collapse
|
23
|
Ruparelia A, McKaige E, Williams C, Schulze K, Fuchs M, Oorschot V, Lacene E, Mirella M, Baxter E, Torrente Y, Ramm G, Stojkovic T, Lavoié J, Bryson-Richardson R. P.77Repurposing of metformin identified as a potential therapy in models of BAG3 myofibrillar myopathy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Oezkan F, He K, Owen D, Pietrzak M, Cho J, Kitzler R, Pearson R, Rusch V, Chaft J, Suh R, Blasberg J, Reckamp K, Raz D, Kneuertz P, Fiorillo L, Garon E, Nicholas A, Johnson A, Schulze K, Grindheim J, Banchereau R, Phan S, Bunn P, Kwiatkowski D, Johnson B, Kris M, Wistuba I, Lee J, Lozanski G, Carbone D. OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.482] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Negrao M, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Hu S, Elamin Y, Le X, Goldberg M, Wu C, Zhang J, Barreto D, Rinsurongkawong W, Simon G, Roth J, Swisher S, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons D, Glisson B, Miller V, Alexander B, Frampton G, Albacker L, Shames D, Zhang J, Heymach J. MA03.05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Müller-Deile J, Schenk H, Schroder P, Schulze K, Bolaños-Palmieri P, Siegerist F, Endlich N, Haller H, Schiffer M. Circulating factors cause proteinuria in parabiotic zebrafish. Kidney Int 2019; 96:342-349. [PMID: 31076096 DOI: 10.1016/j.kint.2019.02.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 12/28/2018] [Accepted: 02/14/2019] [Indexed: 01/17/2023]
Abstract
Proteinuria can be induced by impairment of any component of the glomerular filtration barrier (GFB). To determine the role of circulating permeability factors on glomerular damage, we developed a parabiosis-based zebrafish model to generate a common circulation between zebrafish larvae. A morpholino-mediated knockdown of a podocyte specific gene (nephronectin) was induced in one zebrafish larva which was then fused to an un-manipulated fish. Notably, proteinuria and glomerular damage were present in the manipulated fish and in the parabiotically-fused partner. Thus, circulating permeability factors may be induced by proteinuria even when an induced podocyte gene dysregulation is the initiating cause.
Collapse
Affiliation(s)
- J Müller-Deile
- Department of Medicine/Nephrology, Hannover Medical School, 30625 Hannover, Germany; Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
| | - H Schenk
- Department of Medicine/Nephrology, Hannover Medical School, 30625 Hannover, Germany; Mount Desert Island Biological Laboratory, Salisbury Cove, Maine, USA
| | - P Schroder
- Mount Desert Island Biological Laboratory, Salisbury Cove, Maine, USA
| | - K Schulze
- Institute for Anatomy and Cell Biology, University of Greifswald, Greifswald, Germany
| | - P Bolaños-Palmieri
- Department of Medicine/Nephrology, Hannover Medical School, 30625 Hannover, Germany; Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
| | - F Siegerist
- Institute for Anatomy and Cell Biology, University of Greifswald, Greifswald, Germany
| | - N Endlich
- Institute for Anatomy and Cell Biology, University of Greifswald, Greifswald, Germany
| | - H Haller
- Department of Medicine/Nephrology, Hannover Medical School, 30625 Hannover, Germany; Mount Desert Island Biological Laboratory, Salisbury Cove, Maine, USA
| | - M Schiffer
- Department of Medicine/Nephrology, Hannover Medical School, 30625 Hannover, Germany; Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; Mount Desert Island Biological Laboratory, Salisbury Cove, Maine, USA
| |
Collapse
|
27
|
Rusch V, Chaft J, Johnson B, Wistuba I, Kris M, Lee J, Bunn P, Kwiatkowski D, Reckamp K, Finley D, Haura E, Waqar S, Doebele R, Garon E, Blasberg J, Nicholas A, Schulze K, Phan S, Gandhi M, Carbone D. MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.346] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Blakey R, Ranlund S, Zartaloudi E, Cahn W, Calafato S, Colizzi M, Crespo-Facorro B, Daniel C, Díez-Revuelta Á, Di Forti M, Iyegbe C, Jablensky A, Jones R, Hall MH, Kahn R, Kalaydjieva L, Kravariti E, Lin K, McDonald C, McIntosh AM, Picchioni M, Powell J, Presman A, Rujescu D, Schulze K, Shaikh M, Thygesen JH, Toulopoulou T, Van Haren N, Van Os J, Walshe M, Murray RM, Bramon E. Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains. Psychol Med 2018; 48:1325-1340. [PMID: 29094675 PMCID: PMC6516747 DOI: 10.1017/s0033291717002860] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND A range of endophenotypes characterise psychosis, however there has been limited work understanding if and how they are inter-related. METHODS This multi-centre study includes 8754 participants: 2212 people with a psychotic disorder, 1487 unaffected relatives of probands, and 5055 healthy controls. We investigated cognition [digit span (N = 3127), block design (N = 5491), and the Rey Auditory Verbal Learning Test (N = 3543)], electrophysiology [P300 amplitude and latency (N = 1102)], and neuroanatomy [lateral ventricular volume (N = 1721)]. We used linear regression to assess the interrelationships between endophenotypes. RESULTS The P300 amplitude and latency were not associated (regression coef. -0.06, 95% CI -0.12 to 0.01, p = 0.060), and P300 amplitude was positively associated with block design (coef. 0.19, 95% CI 0.10-0.28, p 0.38). All the cognitive endophenotypes were associated with each other in the expected directions (all p < 0.001). Lastly, the relationships between pairs of endophenotypes were consistent in all three participant groups, differing for some of the cognitive pairings only in the strengths of the relationships. CONCLUSIONS The P300 amplitude and latency are independent endophenotypes; the former indexing spatial visualisation and working memory, and the latter is hypothesised to index basic processing speed. Individuals with psychotic illnesses, their unaffected relatives, and healthy controls all show similar patterns of associations between endophenotypes, endorsing the theory of a continuum of psychosis liability across the population.
Collapse
Affiliation(s)
- R. Blakey
- Division of Psychiatry, University College London, London, UK
| | - S. Ranlund
- Division of Psychiatry, University College London, London, UK
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - E. Zartaloudi
- Division of Psychiatry, University College London, London, UK
| | - W. Cahn
- Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - S. Calafato
- Division of Psychiatry, University College London, London, UK
| | - M. Colizzi
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - B. Crespo-Facorro
- CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Santander, Spain
| | - C. Daniel
- Division of Psychiatry, University College London, London, UK
| | - Á. Díez-Revuelta
- Division of Psychiatry, University College London, London, UK
- Laboratory of Cognitive and Computational Neuroscience – Centre for Biomedical Technology (CTB), Complutense University and Technical University of Madrid, Madrid, Spain
| | - M. Di Forti
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | | | - C. Iyegbe
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - A. Jablensky
- Centre for Clinical Research in Neuropsychiatry, The University of Western Australia, Perth, Western Australia, Australia
| | - R. Jones
- Division of Psychiatry, University College London, London, UK
| | - M.-H. Hall
- Psychology Research Laboratory, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| | - R. Kahn
- Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - L. Kalaydjieva
- Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Perth, Australia
| | - E. Kravariti
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - K. Lin
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
- Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - C. McDonald
- Department of Psychiatry, Clinical Science Institute, National University of Ireland Galway, Ireland
| | - A. M. McIntosh
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, UK
| | | | - M. Picchioni
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - J. Powell
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - A. Presman
- Division of Psychiatry, University College London, London, UK
| | - D. Rujescu
- Department of Psychiatry, Ludwig-Maximilians University of Munich, Munich, Germany
- Department of Psychiatry, Psychotherapy and Psychosomatics, University of Halle Wittenberg, Halle, Germany
| | - K. Schulze
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - M. Shaikh
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
- North East London Foundation Trust, London, UK
| | - J. H. Thygesen
- Division of Psychiatry, University College London, London, UK
| | - T. Toulopoulou
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
- Department of Psychology, Bilkent University, Main Campus, Bilkent, Ankara, Turkey
- Department of Psychology, the University of Hong Kong, Pokfulam Rd, Hong Kong SAR, China
- The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, The Hong Kong Jockey Club Building for Interdisciplinary Research, Hong Kong SAR, China
| | - N. Van Haren
- Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - J. Van Os
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
- Department of Psychiatry and Psychology, Maastricht University Medical Centre, EURON, Maastricht, The Netherlands
| | - M. Walshe
- Division of Psychiatry, University College London, London, UK
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | | | - R. M. Murray
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
| | - E. Bramon
- Division of Psychiatry, University College London, London, UK
- Institute of Psychiatry Psychology and Neuroscience at King’s College London and South London and Maudsley NHS Foundation Trust, London, UK
- Institute of Cognitive Neuroscience, University College London, London, UK
| |
Collapse
|
29
|
Meital L, Windsor M, Maynard A, Schulze K, Magee R, O’Donnell J, Jha P, Perissiou M, Coverdale S, Golledge J, Bailey T, Askew C, Russell F. Small Abdominal Aortic Aneurysm is Associated With Endotoxin Tolerant-Like Macrophage Immunosuppression and Decreased Levels of the Resolution-Directed Mediator PGE2. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Kerr K, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit E, Dingemans AM, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger T, Kammler R, Sumiyoshi T, Molina M, Shames D, Stahel R, Peters S. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann Oncol 2018; 29:200-208. [DOI: 10.1093/annonc/mdx629] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
31
|
Ross H, Kozono D, Urbanic J, Williams T, Dufrane C, Bara I, Gandhi M, Schulze K, Brockman J, Wang X, Vokes E, Stinchcombe T. P3.04-003 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1661] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Bruland D, Schulze K, Harsch S, Pinheiro P, Bauer U. Mental health literacy of teachers and social workers: qualitative interviews and in-depths findings. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.548] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- D Bruland
- Bielefeld University, Centre for Prevention and Intervention in Childhood and Adolescence (CPI), Bielefeld, Germany
| | - K Schulze
- University of Duisburg-Essen, Department of Social Work & Social Policy, Essen, Germany
| | - S Harsch
- University of Education Freiburg, Freiburg, Germany
| | - P Pinheiro
- Bielefeld University, Centre for Prevention and Intervention in Childhood and Adolescence (CPI), Bielefeld, Germany
| | - U Bauer
- Bielefeld University, Centre for Prevention and Intervention in Childhood and Adolescence (CPI), Bielefeld, Germany
| |
Collapse
|
33
|
Ruparelia A, Williams C, McKaige E, Oorschot V, Baxter E, Schulze K, Ramm G, Bryson-Richardson R. Identification of therapies for myofibrillar myopathy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Rustler C, Scheifhacken S, Bühler A, Schulze K, Bonse-Rohmann M, Schweizer I. Strategien zur Implementierung eines Programmes zur Prävention und Reduktion des Tabakkonsums in der Pflegeausbildung. Pneumologie 2016. [DOI: 10.1055/s-0036-1572046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Rao S, Conklin J, Schulze K. Obituary. Neurogastroenterol Motil 2016; 28:156-7. [PMID: 26690875 DOI: 10.1111/nmo.12751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- S Rao
- ANMS & Medical College of Georgia, Augusta, GA, USA
| | - J Conklin
- University of California at Los Angeles, Los Angeles, CA, USA
| | - K Schulze
- University of Iowa, Iowa City, IA, USA
| |
Collapse
|
36
|
Kerr K, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel E, Blackhall F, Molina M, Shames D, Peters S, Stahel R. 3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31647-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Dommisch H, Staufenbiel I, Schulze K, Stiesch M, Winkel A, Fimmers R, Dommisch J, Jepsen S, Miosge N, Adam K, Eberhard J. Expression of antimicrobial peptides and interleukin-8 during early stages of inflammation: An experimental gingivitis study. J Periodontal Res 2015; 50:836-45. [DOI: 10.1111/jre.12271] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2015] [Indexed: 11/28/2022]
Affiliation(s)
- H. Dommisch
- Department of Periodontology and Synoptic Dentistry; Charité - University Medicine Berlin; Berlin Germany
- Department of Oral Health Sciences; Health Science Center; University of Washington; Seattle WA USA
- Department of Periodontology, Operative and Preventive Dentistry; University Hospital Bonn; Bonn Germany
| | - I. Staufenbiel
- Department of Conservative Dentistry, Periodontology and Preventive Dentistry; Hannover Medical School; Hannover Germany
| | - K. Schulze
- Clinic for Dental Prosthetics and Biomedical Materials Science; Hannover Medical School; Hannover Germany
| | - M. Stiesch
- Clinic for Dental Prosthetics and Biomedical Materials Science; Hannover Medical School; Hannover Germany
| | - A. Winkel
- Clinic for Dental Prosthetics and Biomedical Materials Science; Hannover Medical School; Hannover Germany
| | - R. Fimmers
- Institute of Medical Biometry; Informatics and Epidemiology; University of Bonn; Bonn Germany
| | - J. Dommisch
- Department of Periodontology, Operative and Preventive Dentistry; University Hospital Bonn; Bonn Germany
| | - S. Jepsen
- Department of Periodontology, Operative and Preventive Dentistry; University Hospital Bonn; Bonn Germany
| | - N. Miosge
- Research Group for Oral Biology and Tissue Regeneration; Department of Prosthetic Dentistry; University Hospital Göttingen; Göttingen Germany
| | - K. Adam
- Clinic for Dental Prosthetics and Biomedical Materials Science; Hannover Medical School; Hannover Germany
| | - J. Eberhard
- Clinic for Dental Prosthetics and Biomedical Materials Science; Hannover Medical School; Hannover Germany
| |
Collapse
|
38
|
Rustler C, Scheifhacken S, Bühler A, Schulze K, Bonse-Rohmann M, Schweizer I. Mit dem astra-Programm rauchfrei durch die Pflegeausbildung. Pneumologie 2015. [DOI: 10.1055/s-0035-1544680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Gałaj A, Schulze K, Suryakiran P, Thomas F, Descamps D. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG 2014; 122:107-18. [PMID: 25208608 PMCID: PMC4489326 DOI: 10.1111/1471-0528.13070] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/06/2014] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase-III study (NCT00196937). SETTING Six centres in Germany and Poland. POPULATION 488 healthy women (aged 15-55 years, age-stratified into groups: 15-25, 26-45, and 46-55 years) who received three vaccine doses in the primary study. METHODS Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOME MEASURES Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1. RESULTS At 6 years after dose 1, all women were seropositive for anti-HPV-16 and ≥97% were seropositive for anti-HPV-18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV-16 and anti-HPV-18, respectively. In all age groups, GMTs were higher (anti-HPV-16, 9.3-45.1-fold; anti-HPV-18, 4.3-19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81-0.96 (anti-HPV-16) and 0.69-0.84 (anti-HPV-18). Exploratory modelling based on the 6-year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV-18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported. CONCLUSIONS At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups.
Collapse
Affiliation(s)
- T Schwarz
- Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Würzburg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Bubendorf L, Dafni O, Tischler V, Finn S, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel E, Savic S, Martorell M, Tsourti Z, Schulze K, Das-Gupta A, Kerr K, Peters S, Stahel R. Prevalence and Clinical Outcomes for Patients with Met Protein Expression in Patients with Non-Small Cell Lung Cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu348.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Tafreshi AP, Payne N, Sun G, Sylvain A, Schulze K, Bernard C. Inactive GSK3β is disturbed in the spinal cord during experimental autoimmune encephalomyelitis, but rescued by stem cell therapy. Neuroscience 2014; 277:498-505. [PMID: 25064057 DOI: 10.1016/j.neuroscience.2014.07.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 07/10/2014] [Accepted: 07/11/2014] [Indexed: 10/25/2022]
Abstract
Glycogen synthase kinase 3β (GSK3β) is known to control neuroinflammation, however the status of GSK3β in multiple sclerosis, the most common inflammatory demyelinating disease of the CNS, and its animal model EAE, is unknown. In this study, we investigated the expression of phosphorylated GSK3β, the inactive form of GSK3β, in the spinal cords of EAE mice. We demonstrate that while the expression of phosphorylated GSK3β was present in radial astrocytes and neurons of the control mice that received only complete Freund's adjuvant, it was absent in radial astrocytes and significantly lower in neurons of EAE animals. The loss of phosphorylated GSK3β in radial glia and neurons in EAE spinal cords was concurrent with radial glia migration and astrogliosis. This disturbance in the expression of inactive GSK3β was recovered in neurons, but not in the radial glia, after treatment of EAE mice with adipose-derived mesenchymal stem cells capable of inducing a Th2 shift. Collectively, our results suggest a link between inactive GSK3β and modulation of the immune responses during EAE. Thus, we propose that maintenance of GSK3β in its inactive status may play a role in preserving the normal physiology of the spinal cord and amelioration of EAE following stem cell therapy.
Collapse
Affiliation(s)
- A Parvaneh Tafreshi
- Department of Basic Sciences, Faculty of Medical Biotechnology, The National Institute of Genetic Engineering and Biotechnology, Tehran 14965-161, Iran.
| | - N Payne
- Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria 3800, Australia
| | - G Sun
- Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria 3800, Australia
| | - A Sylvain
- Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria 3800, Australia
| | - K Schulze
- Monash Micro Imaging, Monash University, Melbourne, Victoria, Australia
| | - C Bernard
- Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria 3800, Australia
| |
Collapse
|
42
|
Heim D, Cornils K, Schulze K, Fehse B, Lohse AW, Brümmendorf TH, Wege H. Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis. Oncogene 2014; 34:364-72. [DOI: 10.1038/onc.2013.551] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 09/30/2013] [Accepted: 11/03/2013] [Indexed: 12/28/2022]
|
43
|
Schulze K. Management of idiopathic pulmonary fibrosis and pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 Suppl 1:33-36. [PMID: 24081242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Indexed: 06/02/2023]
Abstract
Idiopathic pulmonary fibrosis (IPF) is an untreatable diffuse parenchymal lung disease with a median survival of approximately three years. Pulmonary hypertension (PH) is frequently seen in patients with IPF and is commonly attributed to hypoxic vasoconstriction and capillary destruction. Pathology findings include endothelial proliferation and medial hypertrophy that exceed those expected in the setting of hypoxia. Non-invasive evaluation has limited sensitivity and specificity for the diagnosis of PH in IPF; therefore, right-heart catheterisation remains the 'gold standard' diagnostic test. PH in patients with IPF is associated with decreased exercise capacity and worse survival. Given the grave consequences of this condition, treatment of PH could improve functional outcomes and survival. However, possible treatments such as long-term supplemental oxygen and targeted vascular therapy are either unstudied or remain unproven.
Collapse
Affiliation(s)
- K Schulze
- Klinikum Ernst von Bergmann, Potsdam, Germany.
| |
Collapse
|
44
|
Hausmann J, Naghipour P, Schulze K. Analytical and Numerical Residual Stress Models for Fiber Metal Laminates – Comparison and Application. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.mspro.2013.02.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Alade Y, Tunkel D, Schulze K, McGready J, Jallo G, Ain M, Yost T, Hoover-Fong J. Cross-sectional assessment of pain and physical function in skeletal dysplasia patients. Clin Genet 2012; 84:237-43. [PMID: 23106480 DOI: 10.1111/cge.12045] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 10/22/2012] [Accepted: 10/22/2012] [Indexed: 01/02/2023]
Abstract
Short stature skeletal dysplasia (SD) patients have orthopedic and neurologic complications causing significant pain and physical disability. We conducted a large cross-sectional online survey in 361 people with short stature SD (>10 years) to describe pain prevalence, characteristics, and the relationship between pain and function. Chronic pain prevalence per Brief Pain Inventory (BPI) was 70.3%. Women reported more pain than men (73% vs 63% p = 0.04). Pain Severity Score (average of current, worst, least and average pain) averaged 3.3 ± 2, while the Pain Interference Score (with daily activities) averaged 3.4 ± 2.7 on a 10-point scale. Per Bleck scale, 20.5% had little or no functional capacity. Increasing age and decreased ambulation independently predicted chronic pain. Chronic pain is prevalent in short stature SD patients and associated with poor physical function. Further study is required to clarify the temporal relationship among pain, function and treatments.
Collapse
Affiliation(s)
- Y Alade
- Alan and Kathryn Greenberg Center for Skeletal Dysplasias, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Schwarz T, Romanowski B, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Suryakiran P, Thomas F, Struyf F. O608 IMMUNE RESPONSE TO THE HPV-16/18 AS04-ADJUVANTED VACCINE ADMINISTERED AS A 2-DOSE OR 3-DOSE SCHEDULE UP TO 3 YEARS AFTER VACCINATION. Int J Gynaecol Obstet 2012. [DOI: 10.1016/s0020-7292(12)61038-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Rashid S, Melone M, Tarnopolsky M, Schulze K, Gerstein H, Yusuf S, Anand S. 422 Accelerated Adipose Tissue Dysfunction and Cardiovascular Risk in Individuals of South Asian Ethnicity. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
48
|
Schulze K, Schmiedel S, van Lunzen J. [Immune reconstitution inflammatory syndrome in cryptococcal meningitis: a rare phenomenon?]. Dtsch Med Wochenschr 2012; 137:834-7. [PMID: 22495917 DOI: 10.1055/s-0032-1304867] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
HISTORY AND ADMISSION FINDINGS A 38-year old patient with previously untreated HIV infection presented with progressive cephalgia, photophobia, polydpsia and nausea/vomiting. INVESTIGATIONS Clinical findings revealed a reduced general state of health and focal neurological deficits. Laboratory findings demonstrated a lymphocytopenia. In addition to positive crytococcus culture and antigen titer in cerebrospinal fluid/serum, Cryptococcus neoformans was detected by light microscopy (India ink stain) in cerebrospinal fluid. DIAGNOSIS, TREATMENT AND COURSE A cryptococcal meningitis was diagnosed. After initiating antifungal and antiretroviral treatment the clinical course worsened after months 2, 3, and 5, respectively. Apart from unspecific inflammation in the lab work, no signs of disease relapse or therapy refractory course were found in additional diagnostics. After critical evaluation of the clinical course and diagnostic results, immune reconstitution inflammatory syndrome (IRIS) was diagnosed. Clinical improvement was achieved during adjuvant treatment with steroids within six months. CONCLUSIONS In the presence of neurological symptoms, cryptococcal meningitis is a rare but possible differential diagnosis in daily routine. Diagnosis can be easily achieved by India ink stain in combination with culture of cerebrospinal fluid as well as antigen detection in most cases. Tests of antifungal resistance should be reserved for patients who do not respond to initial treatment, patients with atypical course of disease or failing longterm antifungal therapy. The IRIS is no rare complication after initiation of antiretroviral treatment in HIV associated cryptococcal infections. It is an important differential diagnosis in an atypical course of disease, and sufficient treatment is usually achieved by steroids.
Collapse
Affiliation(s)
- K Schulze
- Sektion Infektiologie und Tropenmedizin, I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf.
| | | | | |
Collapse
|
49
|
Scholl PF, Cole RN, Ruczinski I, Gucek M, Diez R, Rennie A, Nathasingh C, Schulze K, Christian P, Yager JD, Groopman JD, West KP. Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal. Placenta 2012; 33:424-32. [PMID: 22385826 DOI: 10.1016/j.placenta.2012.02.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2011] [Revised: 01/19/2012] [Accepted: 02/08/2012] [Indexed: 10/28/2022]
Abstract
Characterization of normal changes in the serum proteome during pregnancy may enhance understanding of maternal physiology and lead to the development of new gestational biomarkers. In 23 Nepalese pregnant women who delivered at term, two-dimensional difference in-gel electrophoresis (DIGE) was used to assess changes in relative protein abundance between paired serum samples collected in the first and third trimesters. One-hundred and forty-five of over 700 protein spots in DIGE gels (pI 4.2-6.8) exhibited nominally significant (p < 0.05) differences in abundance across trimesters. Additional filtering using a Bonferroni correction reduced the number of significant (p < 0.00019) spots to 61. Mass spectrometric analysis detected 38 proteins associated with gestational age, cytoskeletal remodeling, blood pressure regulation, lipid and nutrient transport, and inflammation. One new protein, pregnancy-specific β-glycoprotein 4 was detected. A follow-up isotope tagging for relative and absolute quantitation (iTRAQ) experiment of six mothers from the DIGE study revealed 111 proteins, of which 11 exhibited significant (p < 0.05) differences between trimesters. Four of these proteins: gelsolin, complement C1r subcomponent, α-1-acid glycoprotein, and α-1B-glycoprotein also changed in the DIGE analysis. Although not previously associated with normal pregnancy, gelsolin decreased in abundance by the third trimester (p < 0.01) in DIGE, iTRAQ and Western analyses. Changes in abundance of proteins in serum that are associated with syncytiotrophoblasts (gelsolin, pregnancy-specific β-1 glycoprotein 1 and β-2-glycoprotein I) probably reflect dynamics of a placental proteome shed into maternal circulation during pregnancy. Measurement of changes in the maternal serum proteome, when linked with birth outcomes, may yield biomarkers for tracking reproductive health in resource poor settings in future studies.
Collapse
Affiliation(s)
- P F Scholl
- Johns Hopkins University, Bloomberg School of Public Health, Department of Environmental Health Sciences, 615 N. Wolfe St., Baltimore, MD 21205-2200, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Groome P, O’Sullivan B, Mackillop W, Irish J, Schulze K, Jackson L, Bissett R, Dixon P, Eapen L, Gulavita S, Hammond J, Hodson D, Mackenzie R, Schneider K, Warde P. Laryngeal Cancer Treatment and Survival Differences across Regional Cancer Centres in Ontario, Canada. Clin Oncol (R Coll Radiol) 2011; 23:19-28. [DOI: 10.1016/j.clon.2010.08.027] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2009] [Revised: 06/07/2010] [Accepted: 06/09/2010] [Indexed: 11/26/2022]
|